Literature DB >> 27390360

Definition of bulky disease in early stage Hodgkin lymphoma in computed tomography era: prognostic significance of measurements in the coronal and transverse planes.

Anita Kumar1, Irene A Burger2, Zhigang Zhang3, Esther N Drill3, Jocelyn C Migliacci4, Andrea Ng5, Ann LaCasce6, Darci Wall7, Thomas E Witzig7, Kay Ristow7, Joachim Yahalom8, Craig H Moskowitz4, Andrew D Zelenetz4.   

Abstract

Disease bulk is an important prognostic factor in early stage Hodgkin lymphoma, but its definition is unclear in the computed tomography era. This retrospective analysis investigated the prognostic significance of bulky disease measured in transverse and coronal planes on computed tomography imaging. Early stage Hodgkin lymphoma patients (n=185) treated with chemotherapy with or without radiotherapy from 2000-2010 were included. The longest diameter of the largest lymph node mass was measured in transverse and coronal axes on pre-treatment imaging. The optimal cut off for disease bulk was maximal diameter greater than 7 cm measured in either the transverse or coronal plane. Thirty patients with maximal transverse diameter of 7 cm or under were found to have bulk in coronal axis. The 4-year overall survival was 96.5% (CI: 93.3%, 100%) and 4-year relapse-free survival was 86.8% (CI: 81.9%, 92.1%) for all patients. Relapse-free survival at four years for bulky patients was 80.5% (CI: 73%, 88.9%) compared to 94.4% (CI: 89.1%, 100%) for non-bulky; Cox HR 4.21 (CI: 1.43, 12.38) (P=0.004). In bulky patients, relapse-free survival was not impacted in patients treated with chemoradiotherapy; however, it was significantly lower in patients treated with chemotherapy alone. In an independent validation cohort of 38 patients treated with chemotherapy alone, patients with bulky disease had an inferior relapse-free survival [at 4 years, 71.1% (CI: 52.1%, 97%) vs 94.1% (CI: 83.6%, 100%), Cox HR 5.27 (CI: 0.62, 45.16); P=0.09]. Presence of bulky disease on multidimensional computed tomography imaging is a significant prognostic factor in early stage Hodgkin lymphoma. Coronal reformations may be included for routine Hodgkin lymphoma staging evaluation. In future, our definition of disease bulk may be useful in identifying patients who are most appropriate for chemotherapy alone. Copyright© Ferrata Storti Foundation.

Entities:  

Mesh:

Year:  2016        PMID: 27390360      PMCID: PMC5046653          DOI: 10.3324/haematol.2016.141846

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  24 in total

Review 1.  The EORTC strategy in the treatment of Hodgkin's lymphoma.

Authors:  Houchingue Eghbali; John Raemaekers; Patrice Carde
Journal:  Eur J Haematol Suppl       Date:  2005-07

2.  Informatics in radiology (infoRAD): navigating the fifth dimension: innovative interface for multidimensional multimodality image navigation.

Authors:  Antoine Rosset; Luca Spadola; Lance Pysher; Osman Ratib
Journal:  Radiographics       Date:  2006 Jan-Feb       Impact factor: 5.333

3.  Hodgkin's disease with bulky mediastinal involvement: effective management with combined modality therapy.

Authors:  R A Behar; S J Horning; R T Hoppe
Journal:  Int J Radiat Oncol Biol Phys       Date:  1993-04-02       Impact factor: 7.038

4.  Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting.

Authors:  T A Lister; D Crowther; S B Sutcliffe; E Glatstein; G P Canellos; R C Young; S A Rosenberg; C A Coltman; M Tubiana
Journal:  J Clin Oncol       Date:  1989-11       Impact factor: 44.544

5.  Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: Clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial.

Authors:  John M M Raemaekers; Marc P E André; Massimo Federico; Theodore Girinsky; Reman Oumedaly; Ercole Brusamolino; Pauline Brice; Christophe Fermé; Richard van der Maazen; Manuel Gotti; Reda Bouabdallah; Catherine J Sebban; Yolande Lievens; Allessandro Re; Aspasia Stamatoullas; Frank Morschhauser; Pieternella J Lugtenburg; Elisabetta Abruzzese; Pierre Olivier; Rene-Olivier Casasnovas; Gustaaf van Imhoff; Tiana Raveloarivahy; Monica Bellei; Thierry van der Borght; Stephane Bardet; Annibale Versari; Martin Hutchings; Michel Meignan; Catherine Fortpied
Journal:  J Clin Oncol       Date:  2014-03-17       Impact factor: 44.544

6.  Categorizing a prognostic variable: review of methods, code for easy implementation and applications to decision-making about cancer treatments.

Authors:  M Mazumdar; J R Glassman
Journal:  Stat Med       Date:  2000-01-15       Impact factor: 2.373

7.  Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification.

Authors:  Bruce D Cheson; Richard I Fisher; Sally F Barrington; Franco Cavalli; Lawrence H Schwartz; Emanuele Zucca; T Andrew Lister
Journal:  J Clin Oncol       Date:  2014-09-20       Impact factor: 44.544

8.  Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group.

Authors:  Andreas Engert; Petra Schiller; Andreas Josting; Richard Herrmann; Peter Koch; Markus Sieber; Friederike Boissevain; Maike De Wit; Jorg Mezger; Eckhart Duhmke; Normann Willich; Rolf-Peter Muller; Bernhard F Schmidt; Helmut Renner; Hans Konrad Muller-Hermelink; Beate Pfistner; Jurgen Wolf; Dirk Hasenclever; Markus Loffler; Volker Diehl
Journal:  J Clin Oncol       Date:  2003-08-11       Impact factor: 44.544

9.  Randomized comparison of consolidation radiation versus observation in bulky Hodgkin's lymphoma with post-chemotherapy negative positron emission tomography scans.

Authors:  Marco Picardi; Amalia De Renzo; Fabrizio Pane; Emanuele Nicolai; Roberto Pacelli; Marco Salvatore; Bruno Rotoli
Journal:  Leuk Lymphoma       Date:  2007-09

10.  Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma.

Authors:  John Radford; Tim Illidge; Nicholas Counsell; Barry Hancock; Ruth Pettengell; Peter Johnson; Jennie Wimperis; Dominic Culligan; Bilyana Popova; Paul Smith; Andrew McMillan; Alison Brownell; Anton Kruger; Andrew Lister; Peter Hoskin; Michael O'Doherty; Sally Barrington
Journal:  N Engl J Med       Date:  2015-04-23       Impact factor: 91.245

View more
  15 in total

Review 1.  Optimizing the role of brentuximab vedotin in classical Hodgkin lymphoma therapy.

Authors:  Alison J Moskowitz
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

Review 2.  Emerging Therapies in Relapsed and Refractory Hodgkin Lymphoma: What Comes Next After Brentuximab Vedotin and PD-1 Inhibition?

Authors:  Tamer Othman; Alex Herrera; Matthew Mei
Journal:  Curr Hematol Malig Rep       Date:  2021-01-06       Impact factor: 3.952

3.  Maximum tumor diameter is associated with event-free survival in PET-negative patients with stage I/IIA Hodgkin lymphoma.

Authors:  Tim M Illidge; Elizabeth H Phillips; Nicholas Counsell; Ruth Pettengell; Peter W M Johnson; Dominic J Culligan; Bilyana Popova; Laura Clifton-Hadley; Andrew McMillan; Peter Hoskin; Sally F Barrington; John Radford
Journal:  Blood Adv       Date:  2020-01-14

4.  Two distinct prognostic groups in advanced-stage Hodgkin lymphoma revealed by the presence and site of bulky disease.

Authors:  Shunan Qi; Sarah Milgrom; Bouthaina Dabaja; Richard Tsang; Mario Levis; Umberto Ricardi; Rebecca Lopez-Alonso; Eldad J Dann; Andrea Ng; Joachim Yahalom
Journal:  Blood Adv       Date:  2020-05-12

5.  Outcomes and prognostic factors for relapsed or refractory lymphoma patients in phase I clinical trials.

Authors:  Jean-Marie Michot; Lina Benajiba; Laura Faivre; Capucine Baldini; Lelia Haddag; Clement Bonnet; Christophe Massard; Frederic Bigot; Camille Bigenwald; Benjamin Verret; Zoé A P Thomas; Andrea Varga; Anas Gazzah; Antoine Hollebecque; David Ghez; Julien Lazarovici; Rastilav Balheda; Aurore Jeanson; Sophie Postel-Vinay; Alina Danu; Jean-Charles Soria; Xavier Paoletti; Vincent Ribrag
Journal:  Invest New Drugs       Date:  2017-06-09       Impact factor: 3.850

6.  Evolution of lymphoma staging and response evaluation: current limitations and future directions.

Authors:  Joel Cunningham; Sunil Iyengar; Bhupinder Sharma
Journal:  Nat Rev Clin Oncol       Date:  2017-06-13       Impact factor: 66.675

7.  Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma.

Authors:  Anita Kumar; Carla Casulo; Joachim Yahalom; Heiko Schöder; Paul M Barr; Philip Caron; April Chiu; Louis S Constine; Pamela Drullinsky; Jonathan W Friedberg; John F Gerecitano; Audrey Hamilton; Paul A Hamlin; Steven M Horwitz; Alexandra G Jacob; Matthew J Matasar; Gianna N McArthur; Susan J McCall; Alison J Moskowitz; Ariela Noy; Maria L Palomba; Carol S Portlock; David J Straus; Nicholas VanderEls; Stephanie L Verwys; Joanna Yang; Anas Younes; Andrew D Zelenetz; Zhigang Zhang; Craig H Moskowitz
Journal:  Blood       Date:  2016-07-25       Impact factor: 22.113

8.  ABVD followed by BV consolidation in risk-stratified patients with limited-stage Hodgkin lymphoma.

Authors:  Steven I Park; Thomas C Shea; Oludamilola Olajide; Nishitha M Reddy; Lihua E Budde; Nilanjan Ghosh; Allison M Deal; Jeanne F Noe; Stephen M Ansell
Journal:  Blood Adv       Date:  2020-06-09

9.  Gadolinium-enhanced imaging of pediatric thoracic lymphoma: is intravenous contrast really necessary?

Authors:  Christophe T Arendt; Martin Beeres; Doris Leithner; Patricia Tischendorf; Marcel Langenbach; Benjamin Kaltenbach; Jasmin Dalgicdir; Thomas J Vogl; Tatjana Gruber-Rouh
Journal:  Eur Radiol       Date:  2018-12-13       Impact factor: 5.315

10.  Prognostic value of baseline metabolic tumor volume in children and adolescents with intermediate-risk Hodgkin lymphoma treated with chemo-radiation therapy: FDG-PET parameter analysis in a subgroup from COG AHOD0031.

Authors:  Sarah A Milgrom; Jihyun Kim; Alin Chirindel; Jongho Kim; Qinglin Pei; Lu Chen; Allen Buxton; Sandy Kessel; Jeffrey Leal; Kathleen M McCarten; Bradford S Hoppe; Suzanne L Wolden; Cindy L Schwartz; Debra L Friedman; Kara M Kelly; Steve Y Cho
Journal:  Pediatr Blood Cancer       Date:  2021-07-10       Impact factor: 3.838

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.